Five takeaways from its financial results:
1. Revenue in the first quarter was $402.1 million, up 16 percent from the same period last year.
2. Net loss was $31.2 million, or $0.18 per share.
3. Screening revenue, which includes Cologuard tests, increased 10 percent at $240.3 million.
4. Precision oncology revenue was $129.4 million, and COVID-19 testing revenue was $32.3 million.
5. The company expects revenue of $1.7 billion this year, with $1.1 billion of that coming from screening products this year.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
